Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043954 | 1.00 | DNM1 (0.34) | DNM1HIF1ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20243270 | 0.79 | — | — | |
| SCHEMBL476608 | 0.78 | DNM1 (0.40) | DNM1HIF1ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18526904 | 0.77 | — | — | |
| SCHEMBL4859082 | 0.76 | DNM1 (0.33) | DNM1HIF1ALMNASMN1; SMN2HTT | |
| SCHEMBL6263042 | 0.76 | DNM1 (0.33) | DNM1HIF1ALMNASMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL10686188 | 0.76 | HIF1A (0.43) | DNM1HIF1ALMNASMN1; SMN2HTT | |
| SCHEMBL22456 | 0.75 | TSHR (0.41) | LMNAALDH1A1TSHRMAPK1 | |
| SCHEMBL16625900 | 0.74 | TSHR (0.38) | LMNATSHRMAPT | |
| SCHEMBL17261304 | 0.73 | HIF1A (0.38) | DNM1HIF1ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979356-B1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PROD INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| EP-1979356-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007072153-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072153-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | DNM1 1377/4885HIF1A 2624/4885LMNA 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.